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ABSTRACT
Lichen planus is a T-cell–mediated immunological disorder causing inflammatory lesions 
on the skin and oral mucosa. The etiology of lichen planus remains unknown, and the 
current therapeutic strategy is primarily to manage the symptoms. Although topical 
steroids are commonly used in the treatment of lichen planus, there are lesions refractory 
to steroids that require different treatment options. This report is of a patient with bilateral 
erosive oral lichen planus of the buccal mucosa. The lesions did not respond to high-
potency topical steroids, so they were treated with topical tacrolimus 0.1% ointment, a 
potent topical immunosuppressant. All the erosive lesions healed, and the associated 
pain and bleeding disappeared after 6 weeks of treatment.
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Introduction
Lichen planus is a T-cell–mediated immunological disorder causing inflammatory lesions 
on the skin and oral mucosa. The reported prevalence of oral lichen planus (OLP) varies 
from 0.5 to 3.0% of the population 1,2. Clinically, OLP can manifest as reticular, papular, 
plaque-like, erythematous, erosive or bullous subtypes 3. To establish a clinical diagnosis 
of OLP, reticular or papular textures have to be present.
 A biopsy for histopathological examination is usually required for accurate diagnosis 
and to exclude potential malignancy. As the etiology of OLP remains unknown, the current 
therapeutic strategy is primarily to manage the symptoms. Although topical steroids are 
commonly used in the treatment of OLP, there are lesions refractory to steroids that require 
different medications such as immunosuppressive drugs 4,5.
 This report is of a patient with bilateral erosive OLP of the buccal mucosa, which 
was refractory to high-potency topical steroids and required an alternative treatment 
approach. 
Case report
A 48-year-old woman was referred by a general dental practitioner to the Oral Medicine 
Consultation Clinic at The Prince Philip Dental Hospital, The University of Hong Kong, 
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Corticosteroids, retinoids, and calcineurin inhibitors are 
commonly used in the management of symptomatic OLP. 
Retinoids are potentially effective for treating OLP, but are 
probably inferior to topical corticosteroids 6. A single-blind 
randomized study compared a medium-strength topical 
corticosteroid (triamcinolone acetonide) with ciclosporin 
and demonstrated no differences in efficacy between the 
two drugs 7. Another randomized, comparative, double-
blind study reported that clobetasol, a high-potency 
topical corticosteroid, is more effective than ciclosporin in 
inducing clinical improvement 8. Triamcinolone has been 
found to be significantly less effective than clobetasol 9. 
Although numerous studies on the management of OLP 
have been published, there is a lack of randomized placebo-
controlled trials that examine the efficacy of various drug 
treatments for OLP, and there is insufficient evidence to 
support the superior effectiveness of any specific treatment. 
Recommendations for the treatment of OLP are based 
mainly on clinical experiences. 
 The choice of drug for treating OLP depends on the 
severity of discomfort, the site of the lesions, and the general 
health of the patients 10. Triamcinolone acetonide 0.1% 
has been widely used by dental practitioners to manage 
symptomatic OLP because it is safe and readily available 
in dental clinics. Triamcinolone acetonide has intermediate 
potency, and is one of the few topical corticosteroids 
manufactured in a dental paste formula. Treatment with 
triamcinolone acetonide is quite effective when lichen 
planus presents as an erythematous lesion or small erosion. 
However, for extensive erosive lesions, triamcinolone 
acetonide is usually not sufficient or takes too long to control 
the symptoms. Some studies have advocated highly potent 
topical corticosteroids such as clobetasol propionate in favor 
of those with intermediate potency 4,11. After the symptoms 
are controlled using high-potency corticosteroids, either the 
frequency of administration can be reduced or a medium-
potency corticosteroid can be substituted to maintain the 
effect.
 Although topical steroids are commonly used for 
managing OLP, some refractory lesions do not respond to 
corticosteroid treatment. Immunosuppressive drugs are 
an alternative option for treating these refractory lesions. 
Tacrolimus is a calcineurin inhibitor that shares the same 
cellular target as ciclosporin. Both ciclosporin and oral 
Hong Kong, in 2010 to manage ulceration occurring at both 
sides of the buccal mucosa. The patient had had ulceration 
associated with pain and bleeding, particularly during tooth 
brushing and eating hard food, for over 6 months. The 
patient was diagnosed with erosive OLP and treated with 
triamcinolone prescribed by the general dental practitioner.
 Intraoral examination in the clinic revealed two erosive 
lesions of 1.0 x 1.5 cm and 1.5 x 2.0 cm in size surrounded 
with white striae at the left (Fig 1a) and right (Fig 1b) 
buccal mucosa, respectively. Incisional biopsy confirmed 
the diagnosis of erosive OLP. Topical clobetasol propionate 
0.05% ointment, a highly potent topical corticosteroid, was 
prescribed twice daily, and 4% bicarbonate mouthrinse 
was prescribed as prophylaxis for oral candidiasis. After 
3 weeks of treatment, intraoral examination revealed no 
improvement of the symptoms. Clobetasol propionate was 
discontinued and tacrolimus 0.1% ointment twice daily was 
prescribed. After 3 weeks of treatment, the intensity of the 
pain and the size of the erosive lesions were remarkably 
reduced. After 6 weeks, the patient reported that all the 
pain and bleeding had disappeared. Intraoral examination 
revealed normal appearance at both the left (Fig 2a) and 
right (Fig 2b) buccal mucosa. No ulceration or erythematous 
lesions were found. 
Discussion
Various oral lesions such as lichenoid contact reactions, 
lichenoid drug eruptions, and lichenoid reactions of 
graft-versus-host disease (GVHD) have similar clinical 
manifestations as OLP. Histopathological examination cannot 
distinguish OLP from these lichenoid lesions 6. However, 
trigger factors such as a direct topographic relationship 
to dental restorative materials, history of taking certain 
medications, or history of organ transplantation associated 
with lichenoid reactions can usually be identified 6. This 
patient presented with ‘classic’ reticular lichen planus, but 
no risk factors that could trigger lichenoid reactions were 
identified. Considering the medical/dental history, clinical 
manifestation and histopathological finding, a diagnosis of 
OLP was made.
 As the etiology behind OLP is not fully understood and 
no preventive therapies have been developed, currently all 
treatment strategies are aimed at controlling the symptoms. 
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Figure 1 Erosive lichen planus at the (a) left and (b) right buccal 
mucosa
Figure 2 After 6 weeks of treatment with tacrolimus, intraoral 
examination revealed normal appearance at both the (a) left and 
(b) right buccal mucosa
improve before she attended the Oral Medicine Consultation 
Clinic. After a diagnosis of OLP was confirmed by incisional 
biopsy, treatment with clobetasol propionate 0.05% 
ointment, a highly potent topical corticosteroid, was started. 
There was no improvement after 3 weeks of treatment, so 
clobetasol propionate was replaced by tacrolimus 0.1% 
ointment. After 3 weeks, the intensity of the pain and the 
size of the ulceration were remarkably reduced, and all the 
lesions and associated symptoms disappeared after 8 weeks 
of treatment. This patient provides evidence that tacrolimus 
could be used as an alternative treatment for managing 
severe erosive OLP refractory to potent steroids. 
 Some studies have shown that tacrolimus has a lower 
risk for development of oral candidiasis than potent topical 
steroids 16. However, some reports have raised a concern 
tacrolimus are approved for use in organ transplantation 
as part of the immunosuppressive regimen 12. The 
immunosuppressive action of tacrolimus is 10 to 100 times 
more potent than ciclosporin 13. Tacrolimus ointment 
0.1% and cream 0.1% have received approval from the 
US Food and Drug Administration (FDA) on the basis of 
their demonstrated efficacy in the treatment of atopic 
dermatitis refractory to conventional treatment 12. Systemic 
administration of tacrolimus has also been used for 
prevention of GVHD and for treating psoriasis 12-15.
 Tacrolimus has been used successfully for managing 
inflammatory diseases of the skin, and has been used 
alternatively in the treatment of severe erosive OLP that 
does not respond to corticosteroids 14,15. This patient had 
been treated with triamcinolone, but the symptoms failed to 
(a)
(b)
(a)
(b)
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that long-term use of tacrolimus may induce squamous cell 
carcinoma of the skin and oral mucosa 17. The US FDA issued 
a public health advisory to inform health care professionals 
and patients of the potential cancer risk based on animal 
experiments and case reports of a small number of patients 
in 2005 18. The FDA requested that the labeling of tacrolimus 
include a boxed warning about the potential cancer risk, 
and recommended that: (1) continuous long-term use 
of tacrolimus, in any age-group, should be avoided; (2) 
application should be limited to the areas of the lesions; (3) 
treatment is not indicated for use in children younger than 
2 years; and (4) only tacrolimus 0.03% is indicated for use 
in children aged 2 to 15 years 18. Currently, the potential for 
tacrolimus to cause cancer remains theoretical and unknown. 
The American Academy of Dermatology Association Task 
Force Committee stated that there is no solid proof that 
tacrolimus causes skin cancer, and recommended that 
tacrolimus should remain as treatment for inflammatory 
diseases 19. The European Dermatology Forum concurs with 
this advice 20. 
 In summary, tacrolimus 0.1% is an effective drug for 
treating severe erosive OLP. Tacrolimus should only be used 
as second-line treatment for lesions that are refractory to 
potent steroids. Continuous application should not exceed 
8 weeks. 
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